Companies / BOC Sciences / galiximab
BOC Sciences

galiximab | BOC Sciences

Galiximab is a chimeric monoclonal antibody directed against CD80. Galiximab binds to CD80 and induces cross-linking of CD80 molecules and cell-death via ADCC. Galiximab has been investigated for the treatment of relapsed Hodgkin lymphoma.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.
  • See More